



OPEN ACCESS

EDITED BY

Jens Andre Hammerl,
Bundesinstitut für Risikobewertung, Germany

REVIEWED BY

Mhd Baraa Habib,
Hamad Medical Corporation, Qatar
Sibel Yel,
Erciyes University, Türkiye

*CORRESPONDENCE

Heyuan Ding
✉ heyuan.ding@fudan.edu.cn
Zhijun Jie
✉ jiezhjxh@163.com

†These authors share first authorship

RECEIVED 10 February 2025

ACCEPTED 10 June 2025

PUBLISHED 25 June 2025

CITATION

Li J, Yang Z, Wang K, Zha B, Du Y, Shi J,
Jie Z and Ding H (2025) Syndrome of
inappropriate antidiuretic hormone secretion
following extensively drug-resistant *Klebsiella*
pneumoniae associated with complicated
urinary tract infection: a case report.
Front. Med. 12:1574251.
doi: 10.3389/fmed.2025.1574251

COPYRIGHT

© 2025 Li, Yang, Wang, Zha, Du, Shi, Jie and
Ding. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Syndrome of inappropriate antidiuretic hormone secretion following extensively drug-resistant *Klebsiella pneumoniae* associated with complicated urinary tract infection: a case report

Junqing Li^{1,2†}, Zhuo Yang^{3,4†}, Kai Wang^{2,3†}, Bingbing Zha^{2,3},
Yong Du^{1,2}, Jindong Shi^{1,2}, Zhijun Jie^{1,2*} and Heyuan Ding^{2,3,5*}

¹Department of Respiratory and Critical Care Medicine, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China, ²Center of Community-Based Health Research, Fudan University, Shanghai, China, ³Department of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China, ⁴Department of Endocrinology, Luxi County People's Hospital, Yunnan, China, ⁵Department of Endocrinology, Shanghai Xuhui Central Hospital, Fudan University, Shanghai, China

Hyponatremia is strongly associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH). We present an 82-year-old male with refractory hyponatremia unresponsive to the discontinuation of hydrochlorothiazide and comprehensive treatment (fluid restriction, sodium supplementation, and tolvaptan). Two consecutive urine cultures identified extensively drug-resistant *Klebsiella pneumoniae* (XDRKP). After tigecycline treatment, serum sodium returned to normal and remained stable during one-year follow-up. This case suggests a close relationship between XDRKP infection and SIADH, highlighting the need to evaluate drug-resistant pathogens in patients with refractory hyponatremia and the importance of antimicrobial therapy in the management of electrolyte disorders secondary to drug-resistant urinary tract infections.

KEYWORDS

SIADH, hyponatremia, extensively drug-resistant, *Klebsiella pneumoniae*, urinary tract infection

Introduction

Hyponatremia is the most common electrolyte disturbance in clinical practice, occurring in 15 to 30% of hospitalized patients (1). Hyponatremia is associated with many adverse outcomes, such as osteoporosis, fractures, falls, heart failure, increased mortality and morbidity, prolonged hospital stays (2–6). The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the leading cause of hyponatremia in both hospitalized and ambulatory patients (7–9).

Case presentation

An 82-year-old man presented to the emergency department with one-month history of productive cough and fever. Physical examination showed poor mental state, heavy breath sounds, and no peripheral edema. The patient had hypertension and was taking irbesartan

hydrochlorothiazide (150 mg/12.5 mg qd) before admission. The patient also had prostatic hyperplasia and dysuria. Laboratory test showed that the serum sodium was 117 mmol/L on the admission day. Lung CT scan showed mild infection in the upper lobes of both lungs. Ultrasound of the urinary tract showed no significant obstructive disease. According to the patient's condition, irbesartan hydrochlorothiazide was discontinued and symptomatic treatments such as sodium supplement, tolvaptan (15 mg, bid), imipenem/cilastatin (1.0 g, q12h), and irbesartan (150 mg, qd) were given. The patient was also instructed to limit water intake.

After treatments, pulmonary infection was significantly improved, but hyponatremia and fever were not significantly improved. Meanwhile, the patient developed urinary retention and urinary catheterization was performed. Routine urine examination showed complicated urinary tract infection, and two consecutive urine cultures found extensively drug-resistant *Klebsiella pneumoniae* (XDRKP). Sputum cultures did not reveal pathogenic bacteria. Thus, imipenem/cilastatin was discontinued and tigecycline (50 mg q12h) was given to for anti-infection on the seventh day of admission. The patient's serum sodium level was 117 mmol/L on admission and ranged from 117 to 122 mmol/L before tigecycline was administered. The patient's body temperature returned to normal and serum sodium began to rise on the eighth day of admission. The patient's serum sodium completely returned to normal on the eighteenth day (Figure 1). His laboratory data were summarized in Table 1. The diagnosis of SIADH should be based on clinical manifestations, laboratory tests, imaging and medical history, and other causes of hyponatremia should be excluded. One year after discharge, the patient's serum sodium level was 143 mmol/L.

Discussion

SIADH is a common cause of hyponatremia, which can be secondary to malignancy, central nervous system disorders, medications, pulmonary diseases, and inflammatory diseases (10–13). In this case, although the patient had used thiazides before admission, irbesartan hydrochlorothiazide had been discontinued on admission. The treatments such as sodium supplementation, fluid restriction, and anti-infection were given. After comprehensive treatment, the patient's pneumonia and urinary retention had improved, but the serum sodium level remained low. Ultrasound of the urinary tract showed

no significant obstructive disease. Other tests revealed no evidence of adrenal insufficiency, hypothyroidism, malignancy, or central nervous system disease. Serum sodium began to rise after tigecycline treatment, suggesting a close relationship between hyponatremia and XDRKP infection. One year later, the examination of blood sodium was normal. These evidences indicated that XDRKP infection was the cause of SIADH.

In 2013, Babar SM reported that a 68-year-old Caucasian woman experienced two episodes of SIADH during ciprofloxacin treatment for a urinary tract infection (14). In that case, the ciprofloxacin was discontinued on admission, and her sodium levels rose. Therefore, the cause of SIADH in the case was considered to be related to ciprofloxacin treatment and not to the urinary tract infection. Another case was reported by Roperio-Luis G in 2023, which a 54-year-old man presented with symptoms of dysuria and cloudy urine, as well as a history of passing stool in urine and recurrent urinary tract infections over the past 3 months, with a final diagnosis of SIADH with bladder fistula due to chronic diverticulitis perforation (15).

Urinary tract infection is a common cause of SIADH. At present, the mechanism between urinary tract infection and hyponatremia has not been fully elucidated (7). Lipopolysaccharide (LPS) and inflammatory mediators (such as IL-1 β , IL-6, and TNF- α) contribute to the pathogenesis of hyponatremia. LPS and inflammatory mediators stimulate AVP neurons in the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus, resulting in increased AVP secretion (16–19). AVP acts on V2 receptors in the renal collecting duct to activate the cAMP-PKA pathway, enabling the aquaporin AQP2 to embed into the luminal membrane. This results in increased water reabsorption, urinary concentration (increased urinary osmolal pressure), and inhibition of the renin-angiotensin-aldosterone system (RAAS), which leads to the development of hyponatremia (20). *Klebsiella pneumoniae* (KP) is one of the most clinically relevant species responsible for community-acquired and nosocomial infections in immunocompromised individuals, including pneumonias, urinary tract infections, bacteremia, and liver abscesses (21). Carbapenems are important antibacterial drugs for the treatment of such infections. However, in recent years, the isolation rate of carbapenem-resistant *Klebsiella pneumoniae* (CRKP) has gradually increased. XDRKP was defined as *Klebsiella pneumoniae* that is only sensitive to one or two classes of antibacterial drugs.

SIADH is a biochemical and clinical syndrome of euvolemic hyponatremia, occurring when the antidiuretic effect of arginine vasopressin is enhanced (22). Therefore, volume status can assist in the diagnosis of hyponatremia caused by different causes. Measuring serum osmolality is very useful when plasma sodium is below 135 mmol/L for no apparent reason. SIADH should be suspected in patient with hypoosmotic hyponatremia (low plasma osmolality) and urine osmolality >100 mOsm/kg (23).

The diagnosis of SIADH requires the exclusion of other possible causes of hyponatremia and increased urinary sodium, and must meet some criteria. At present, the criteria described in the first cases published by Schwartz and Bartter and re-issued by Schwartz et al. is still used (13). Management of SIADH begins with a good clinical history and physical examination, as well as laboratory tests, which are essential to discover the details and determine the cause. Once the diagnosis of SIADH, appropriate treatments can be determined based on the cause.




FIGURE 1

Temperature and serum sodium concentration over time. Serum sodium level was 117 mmol/L on the admission day. Initially sodium supplementation and tolvaptan was attempted. Given the lack of response, tigecycline (50 mg q12h) was given to treat the infection. Serum sodium began to rise gradually, and finally back to normal.

TABLE 1 Laboratory values, including initial presentation, and hospital course, including serum and urine electrolytes, as well as serum and urine osmolality.

Lab element (normal value)	Hospital day						
	1	2	6	10	12	14	18
Serum Na, mmol/L (135–145 mmol/L)	117	119	122	121	130	136	141
Serum K, mmol/L (3.5–5.5 mmol/L)	4.2	4.3	4.1	3.5	3.6	4.5	3.6
Serum Cl, mmol/L (96–108 mmol/L)	86	86	86	89	93	101	104
Serum UN, mmol/L (2.78–8.07 mmol/L)	6.5	5.7	5		3.5	7.5	3.6
Serum Crea, μ mol/L (59–104 μ mol/L)	88	76	81		75	92	69
Serum OSM, mOsm/kg (275–295 mOsm/kg)	246.6	251.6	256.7	254.4	271.7	285.3	293.6
Urine Na, mEq/L (20 mEq/L)		123		121			
Urine K, mEq/L (20 mEq/L)		17.3		16.3			
Urine Crea, mg/dL (39–259 mg/dL)		4,464					
Urine Osm, mOsm/kg (300–1,000 mOsm/kg)		561.2		549.2			
TSH, uIU/mL (0.270–4.20 mIU/L)		1.47					
Cortisol, pmol/l (138–480 pmol/L)		403					

Na, sodium; K, potassium; Cl, Chlorine; UN, urea nitrogen; Crea, creatinine; OSM, osmolality; TSH, thyrotropin.

Conclusion

Although the relationship between XDRKP and SIADH remains to be investigated, it is necessary to master the diagnosis and treatment of hyponatremia in clinical practice.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by the ethics committee of Shanghai Fifth People’s Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.

Author contributions

JL: Writing – original draft, Writing – review & editing. ZY: Writing – original draft. KW: Formal analysis, Writing – original draft. BZ: Writing – review & editing. YD: Writing – review & editing. JS: Writing – review & editing. ZJ: Writing – review & editing. HD: Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the Construction Plan of Key Disciplines in Shanghai Municipal Health System (2024ZDXK0017), the Medical Specialized Department Project of Minhang District (2025MWFC07), and the Natural Science Foundation of Xuhui District (SHXH202415).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The authors declare that no Gen AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. *Am J Med.* (2006) 119:S30–5. doi: 10.1016/j.amjmed.2006.05.005
- Corona G, Giuliani C, Parenti G, Norello D, Verbalis JG, Forti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. *PLoS One.* (2013) 8:e80451. doi: 10.1371/journal.pone.0080451
- Holland-Bill L, Christiansen CF, Heide-Jørgensen U, Ulrichsen SP, Ring T, Jørgensen JO, et al. Hyponatremia and mortality risk: a Danish cohort study of 279508 acutely hospitalized patients. *Eur J Endocrinol.* (2015) 173:71–81. doi: 10.1530/eje-15-0111
- Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. *Arch Intern Med.* (2010) 170:294–302. doi: 10.1001/archinternmed.2009.513
- Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatremia. *J Natl Med Assoc.* (2004) 96:1305–8.
- Gill G, Huda B, Boyd A, Skagen K, Wile D, Watson I, et al. Characteristics and mortality of severe hyponatraemia--a hospital-based study. *Clin Endocrinol.* (2006) 65:246–9. doi: 10.1111/j.1365-2265.2006.02583.x
- Adrogué HJ, Madias NE. The syndrome of inappropriate Antidiuresis. *N Engl J Med.* (2023) 389:1499–509. doi: 10.1056/NEJMcp2210411
- Peri A, Pirozzi N, Parenti G, Festuccia F, Menè P. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). *J Endocrinol Investig.* (2010) 33:671–82. doi: 10.1007/bf03346668
- Fenske W, Maier SK, Blechschmidt A, Allolio B, Störk S. Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study. *Am J Med.* (2010) 123:652–7. doi: 10.1016/j.amjmed.2010.01.013
- Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *Am J Med.* (2013) 126:S1–S42. doi: 10.1016/j.amjmed.2013.07.006
- Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. *N Engl J Med.* (2007) 356:2064–72. doi: 10.1056/NEJMcp066837
- Mifsud S, Zammit MA, Casha R, Fsadni C. Influenza a: another cause of SIADH? *BMJ Case Rep.* (2018) 2018:bcr2018226154 doi: 10.1136/bcr-2018-226154
- Christ-Crain M, Hoorn EJ, Sherlock M, Thompson CJ, Wass JAH. ENDOCRINOLOGY IN THE TIME OF COVID-19: management of diabetes insipidus and hyponatraemia. *Eur J Endocrinol.* (2020) 183:G9–g15. doi: 10.1530/eje-20-0338
- Babar SM. SIADH associated with ciprofloxacin. *Ann Pharmacother.* (2013) 47:1359–63. doi: 10.1177/1060028013502457
- Ropero-Luis G. Syndrome of inappropriate Antidiuresis due to chronic perforated diverticulitis with Colovesical fistula. *Cureus.* (2023) 15:e35007. doi: 10.7759/cureus.35007
- Landgraf R, Neumann I, Holsboer F, Pittman QJ. Interleukin-1 beta stimulates both central and peripheral release of vasopressin and oxytocin in the rat. *Eur J Neurosci.* (1995) 7:592–8. doi: 10.1111/j.1460-9568.1995.tb00663.x
- Palin K, Moreau ML, Sauviant J, Orcel H, Nadjar A, Duvoud-Guillou A, et al. Interleukin-6 activates arginine vasopressin neurons in the supraoptic nucleus during immune challenge in rats. *Am J Physiol Endocrinol Metab.* (2009) 296:E1289–99. doi: 10.1152/ajpendo.90489.2008
- Matsunaga W, Miyata S, Takamata A, Bun H, Nakashima T, Kiyohara T. LPS-induced Fos expression in oxytocin and vasopressin neurons of the rat hypothalamus. *Brain Res.* (2000) 858:9–18. doi: 10.1016/S0006-8993(99)02418-X
- Wei R, Phillips TM, Sternberg EM. Specific up-regulation of CRH or AVP secretion by acetylcholine or lipopolysaccharide in inflammatory susceptible Lewis rat fetal hypothalamic cells. *J Neuroimmunol.* (2002) 131:31–40. doi: 10.1016/S0165-5728(02)00251-5
- Ishikawa SE, Schrier RW. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. *Clin Endocrinol.* (2003) 58:1–17. doi: 10.1046/j.1365-2265.2003.01647.x
- Lee CR, Lee JH, Park KS, Jeon JH, Kim YB, Cha CJ, et al. Antimicrobial resistance of Hypervirulent *Klebsiella pneumoniae*: epidemiology, Hypervirulence-associated determinants, and resistance mechanisms. *Front Cell Infect Microbiol.* (2017) 7:483. doi: 10.3389/fcimb.2017.00483
- Crowley RK, Thompson CJ. Syndrome of inappropriate antidiuresis. *Expert Rev Endocrinol Metab.* (2006) 1:537–47. doi: 10.1586/17446651.1.4.537
- Hodax JK, Bialo SR, Yalcindag A. SIADH in systemic JIA resolving after treatment with an IL-6 inhibitor. *Pediatrics.* (2018) 141:141. doi: 10.1542/peds.2016-4174